Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
5(42%)
Results Posted
100%(6 trials)

Phase Distribution

Ph phase_1
8
67%
Ph phase_2
2
17%
Ph phase_3
2
17%

Phase Distribution

8

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
8(66.7%)
Phase 2Efficacy & side effects
2(16.7%)
Phase 3Large-scale testing
2(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

5

trials recruiting

Total Trials

12

all time

Status Distribution
Active(6)
Completed(6)

Detailed Status

Completed6
Recruiting3
Active, not recruiting2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
5
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 18 (66.7%)
Phase 22 (16.7%)
Phase 32 (16.7%)

Trials by Status

recruiting325%
active_not_recruiting217%
completed650%
not_yet_recruiting18%

Recent Activity

Clinical Trials (12)

Showing 12 of 12 trials
NCT06151574Phase 3

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Active Not Recruiting
NCT06324357Phase 1

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Recruiting
NCT06581432Phase 2

Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations

Recruiting
NCT07195695Phase 3

Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Recruiting
NCT07486817Phase 2

Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab

Not Yet Recruiting
NCT04886804Phase 1

Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

Active Not Recruiting
NCT06504862Phase 1

A Study in Healthy Men to Test Whether Zongertinib Influences the Amount of 4 Other Medicines (Dabigatran, Rosuvastatin, Metformin, and Furosemide) in the Blood

Completed
NCT06494761Phase 1

A Study in Healthy Men to Test Whether Zongertinib Affects How 3 Other Medicines (Midazolam, Omeprazole, and Repaglinide) Are Taken up and Processed by the Body

Completed
NCT06028464Phase 1

A Study in Healthy Men to Test Whether Carbamazepine Influences the Amount of Zongertinib in the Blood

Completed
NCT05879991Phase 1

A Study in Healthy Men to Test How Zongertinib (BI 1810631) is Taken up and Processed by the Body

Completed
NCT06075277Phase 1

A Study in Healthy Men to Test How Zongertinib is Taken up in the Body When Taken With or Without Food

Completed
NCT05833139Phase 1

A Study in Healthy Men to Test How Itraconazole Influences the Amount of Zongertinib (BI 1810631) in the Blood

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12